University of Alabama at Birmingham
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).
University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.
University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,160 total, page 17 of 24
University of Alabama at Birmingham (UAB) Pediatric CBD Program
NCT02695537
Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE)
NCT02374827
Preventing Sickle Cell Kidney Disease
NCT02373241
A Website to Teach Children Safety With Dogs
NCT02299427
Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease
NCT02497300
A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)
NCT02477319
A Novel Neurorehabilitation Approach for Cognitive Aging With HIV
NCT02391311
Patient NAVIgation to Reduce Readmissions Among Black Men With Heart Disease
NCT02340364
A Sleep and Media Use Intervention to Improve Adolescents' Weight and Risk of Type 2 Diabetes
NCT02451436
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates
NCT02443389
Effect of Sedation on Cognitive Performance in the Elderly
NCT03089866
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
NCT02520063
Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes
NCT02372253
Speed of Processing Training in Patients With Parkinson's Disease and Healthy Older Adults
NCT02929758
Randomized Controlled Trial of Treatment of Male Partners of Women With BV
NCT02209519
Randomized Controlled Trial of Higher-Volume Feedings in Preterm Neonates
NCT02377050
Egg Diet to Improve Metabolic Health and Function
NCT02760641
The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes
NCT02002130
A Randomized Controlled Trial of Oral Acetaminophen for Analgesic Control After Transvaginal Oocyte Retrieval
NCT02418182
An Alternative Treatment for Cervical Intraepithelial Neoplasia Using the Focal Loop Electrosurgical Excision Procedure
NCT02220192
Lakeshore Examination of Activity and Disability Exercise Response Study
NCT02533882
Adductor Canal Block Versus Femoral Nerve Block for Total Knee Arthroplasty
NCT03133481
Diagnosis of PD and PD Progression Using DWI
NCT02837172
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
NCT02158507
Home-based, Individually-tailored Physical Activity Print Intervention for African American Women in the Deep South
NCT02574689
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
NCT02022423
Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women
NCT02272231
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
NCT02195973
Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors
NCT02224430
Evaluation of a Telehealth Lifestyle Management Program to Improve Healthy Behaviors Post Head Injury
NCT02223728
Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice
NCT02277834
Remote Ischemic Preconditioning Living Donor Renal Transplant Protocol
NCT03084666
Center of Research Translation (CORT) Project 2
NCT02038179
Effects of Diet and Exercise on Ductal Carcinoma in Situ
NCT02224807
Non-Surgical Treatment for Rotator-Cuff Tears Using Platelet-Rich-Plasma
NCT02246530
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
NCT02096471
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
NCT02101736
Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study
NCT02139007
BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients
NCT01782209
Investigation of Non-Invasive Outcomes Predictors in Patients Undergoing DBS for Movement Disorders
NCT02488837
Post-bypass Prophylactic IVIG in Infants and Neonates
NCT02043379
Icodextrin Effects on Glucose Transporter Activation and Mediators of Fibrosis
NCT02133313
Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
NCT02047253
Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors
NCT02150148
Low Dose Naltrexone (LDN) Immune Monitoring
NCT02107014
Influence of Ambient Temperature on Food Intake Through a Randomized Control Trial in an Office Setting
NCT02386891
Evaluating Expectancy Effects in Weight Loss Measurement
NCT02101658
Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders
NCT02476513
Leader Partner Interactions
NCT02048774
Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
NCT01919723
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 129 |
| Phase 2 | 130 |
| Phase 3 | 25 |
| Phase 4 | 72 |
Therapeutic Areas
What is open in the University of Alabama at Birmingham pipeline
216 recruiting of 1,160 indexed (19% open); 723 completed (62%).
Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Alabama at Birmingham: open-pipeline peers nationwide
Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,160 trials (± recruiting share)
- NYU Langone Health · 1,164 trials · 17% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 19% open enrollment (± trial volume)
- University of Minnesota · 19% recruiting · 966 trials
- Mclean Hospital · 19% recruiting · 140 trials
- Children's Hospital Medical Center, Cincinnati · 19% recruiting · 571 trials
- Arkansas Children's Hospital Research Institute · 19% recruiting · 97 trials
Related
What to do with this University of Alabama at Birmingham page
1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.
- 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.